Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Epigenetic regulation in breast cancer

FY 2013-14

Summary
Cell survival, growth and proliferation are dependent upon various growth factors. They typically act as signalling molecules that bind to specific receptors on the surface of their target cells. The receptors for these growth factors and the pathways they initiate are under tight regulation. Any disruption in normal signalling could cause the cell to become cancerous. The protein PHIP1 (Pleckstrin homology domain interacting protein) was shown by our lab to be involved in one such signalling cascade known as the Insulin Growth Factor (IGF) pathway. We have seen that PHIP1 protein levels are much higher in human breast cancer cell lines and clinical samples, as well as mice mammary tumor models. Further, if we were to artificially increase PHIP1 protein levels in normal breast cells, we see changes in their functional characteristics. The cells tend to divide more frequently than normal, show resistance to agents that normally kill, and grow in unfavorable conditions, all features of cancerous cells. I want to find the mechanism by which PHIP1 reprograms these normal breast cells into cancerous cells. I plan on using a tightly regulated system that can switch the levels of artificial PHIP1 within normal breast cells on and off. This will allow me to determine whether or not increasing the levels of PHIP1 is sufficient for driving various cancerous changes that we see in patients within the clinic, including the ability of cells to detach from one another and migrate, altered cell size and shape, increases in cell metabolism, and the ability of the cells to form tumors in mice. We can also evaluate the DNA within these cancerous cells to determine if there are any marked differences in structure as a result of this transformation. All of these changes can be evaluated using standard biochemical and molecular biological techniques within the laboratory. Moreover, we can breed mice that normally form tumors with others in order to erase all PHIP1 protein levels in the mammary gland. This will determine if absence of PHIP1 removes all traces of tumor formation. The work proposed here is quite significant. It will further our understanding of breast cancer development and may also provide us with a potential therapeutic target for future treatment.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311860
Name
Scalia Anthony
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Epigenetic regulation in breast cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Biology; Chromatin Remodeling; Epigenetics; Epithelial-To-Mesenchymal Transitions; Glycolytic Switches; Mammary Tumorigenesis; Oncogenesis; Signalling Cascades; Tumor Metabolism
Abstract
Cell survival, growth and proliferation are dependent upon various growth factors. They typically act as signalling molecules that bind to specific receptors on the surface of their target cells. The receptors for these growth factors and the pathways they initiate are under tight regulation. Any disruption in normal signalling could cause the cell to become cancerous. The protein PHIP1 (Pleckstrin homology domain interacting protein) was shown by our lab to be involved in one such signalling cascade known as the Insulin Growth Factor (IGF) pathway. We have seen that PHIP1 protein levels are much higher in human breast cancer cell lines and clinical samples, as well as mice mammary tumor models. Further, if we were to artificially increase PHIP1 protein levels in normal breast cells, we see changes in their functional characteristics. The cells tend to divide more frequently than normal, show resistance to agents that normally kill, and grow in unfavorable conditions, all features of cancerous cells. I want to find the mechanism by which PHIP1 reprograms these normal breast cells into cancerous cells. I plan on using a tightly regulated system that can switch the levels of artificial PHIP1 within normal breast cells on and off. This will allow me to determine whether or not increasing the levels of PHIP1 is sufficient for driving various cancerous changes that we see in patients within the clinic, including the ability of cells to detach from one another and migrate, altered cell size and shape, increases in cell metabolism, and the ability of the cells to form tumors in mice. We can also evaluate the DNA within these cancerous cells to determine if there are any marked differences in structure as a result of this transformation. All of these changes can be evaluated using standard biochemical and molecular biological techniques within the laboratory. Moreover, we can breed mice that normally form tumors with others in order to erase all PHIP1 protein levels in the mammary gland. This will determine if absence of PHIP1 removes all traces of tumor formation. The work proposed here is quite significant. It will further our understanding of breast cancer development and may also provide us with a potential therapeutic target for future treatment.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Scalia, Anthony
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~